Literature DB >> 30863599

Regionally surgical resection of stage-IV adenocarcinoma acquired tyrosine kinases inhibitor-resistance.

Minglei Yang1, Enkuo Zheng1, Xiang Xu1, Junjun Ni1, Junfang Li1, Guofang Zhao1.   

Abstract

Entities:  

Year:  2019        PMID： 30863599      PMCID： PMC6384361          DOI： 10.21037/jtd.2018.12.105

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  2 in total

1.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.

Authors:  Weijing Cai; Dongmei Lin; Chunyan Wu; Xuefei Li; Chao Zhao; Limou Zheng; Shannon Chuai; Ke Fei; Caicun Zhou; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2015-09-28       Impact factor: 44.544

2.  Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.

Authors:  Fedor V Moiseyenko; Vladimir M Moiseyenko; Svetlana N Aleksakhina; Vyacheslav A Chubenko; Nikita M Volkov; Kseniya S Kozyreva; Michail M Kramchaninov; Alexandr S Zhuravlev; Kseniya V Shelekhova; Alexandr O Ivantsov; Aigul R Venina; Elena V Preobrazhenskaya; Natalia V Mitiushkina; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Oncol Res Treat       Date:  2016-09-15       Impact factor: 2.825
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.